REFERENCES



Choose an author or browse all
Choose the species or browse all
Choose a criteria for sorting
 Reverse sorting
Search for a protein
Search for a single PMID
Select O-GlcNAc references filter

Click to expand (2 results)


Massman LJ, Pereckas M, Zwagerman NT, Olivier-Van Stichelen S. O-GlcNAcylation Is Essential for Rapid Pomc Expression and Cell Proliferation in Corticotropic Tumor Cells. Endocrinology 2021 162(12) 34418053
Abstract:
Pituitary adenomas have a staggering 16.7% lifetime prevalence and can be devastating in many patients because of profound endocrine and neurologic dysfunction. To date, no clear genomic or epigenomic markers correlate with their onset or severity. Herein, we investigate the impact of the O-GlcNAc posttranslational modification in their etiology. Found in more than 7000 human proteins to date, O-GlcNAcylation dynamically regulates proteins in critical signaling pathways, and its deregulation is involved in cancer progression and endocrine diseases such as diabetes. In this study, we demonstrated that O-GlcNAc enzymes were upregulated, particularly in aggressive adrenocorticotropin (ACTH)-secreting tumors, suggesting a role for O-GlcNAcylation in pituitary adenoma etiology. In addition to the demonstration that O-GlcNAcylation was essential for their proliferation, we showed that the endocrine function of pituitary adenoma is also dependent on O-GlcNAcylation. In corticotropic tumors, hypersecretion of the proopiomelanocortin (POMC)-derived hormone ACTH leads to Cushing disease, materialized by severe endocrine disruption and increased mortality. We demonstrated that Pomc messenger RNA is stabilized in an O-GlcNAc-dependent manner in response to corticotrophin-releasing hormone (CRH). By affecting Pomc mRNA splicing and stability, O-GlcNAcylation contributes to this new mechanism of fast hormonal response in corticotropes. Thus, this study stresses the essential role of O-GlcNAcylation in ACTH-secreting adenomas' pathophysiology, including cellular proliferation and hypersecretion.
O-GlcNAc proteins:
GPTC8, ITB4, PTPRF, VIR, HMCN2, SETX, RTF1, MYH7B, FSIP2, ARGAL, CO6A5, MMRN2, STOX1, PLXB2, AGRG4, F25A2, LOXH1, HMCN1, TM233, PIEZ1, TOPZ1, CE350, M3K19, RYR2, ACACB, RN213, CF251, ARHG5, BICRA, FOXM1, DLDH, PEX5, WRN, CELR1, PROM1, STK10, MYPC3, DTNB, IKKB, ACTN3, ALDOC, RPB1, LMNB1, MAP1B, HVM57, PAI1, MCM3, MIS, RGRF1, MSRE, CTND1, RB22A, ZO1, QOR, ANXA5, MSH6, EVC, KCNN2, DEPD5, NOE3, TBB4B, ROCK1, GSH1, G3BP1, ATS1, TBB5, NF1, PGBM, IF2P, FA8, GDF3, KCMA1, ZCH18, TANC1, NSUN7, SHRM4, FAT4, IGFN1, HMHA1, FA98A, SCRN3, CH048, K22E, SHLD2, BIG3, SDK1, BAHC1, SLMAP, TBCD9, RIMB3, DYH12, ITAD, CKAP2, IGS10, A3LT2, ITA1, HERC2, XIRP2, TR150, IQEC2, LRC8B, FAT2, S39AC, VP13A, MTUS1, GSTCD, TENS3, ACACA, UTP20, KLRA4, PAPOA, STAR3, EWS, KTN1, GRID1, DDX5, CP131, SEM3B, TLL1, MINT, CCPG1, BTF3, TPP2, RBL1, COBA2, TASOR, PDS5A, CE290, NAL14, A2MG, ZZZ3, FREM2, CPSF6, RPRD2, HEAT6, P4R3A, FIL1L, SNX6, GAPD1, PTN23, TRI37, MON1A, MSL1, SARM1, CENPE, DAPLE, TIAM2, UBE2O, KDM3B, SYNE1, CMYA5, FHOD3, TBB2A, MYCB2, SGO2, MCAF1, STAR9, CAPS1, PHF8, CUL9, CLAP1, ST18, SGSM2, TAF1, M18BP, UBP2L, FLNB, OFD1, PTHB1, PDK1, TMCO3, NRDC, MARF1, TM87B, UNC80, TCAF1, KTU, UBP43, CAPS2, ZN609, DOCK2, RHG24, NAKD2, LENG8, UFL1, CD158, CLASR, SSPO, SLTM, NAV1, FBX4, RFWD3, MICA3, STAU2, NEIL3, CCD14, DDX18, UBP45, AL1L1, CCD80, TF2H3, FYCO1, HNRPU, DYH5, DHX36, AGRV1, FLNC, REST, NDUS1, CREL1, CELR3, DYST, BRWD1, GOGA2, PDIA6, TM1L1, RT4I1, CSTN3, PRP19, TARA, UBP16, NOG2, MYO7B, BCDO2, RRBP1, ZN318, DHX30, MITOS, RBM33, NARF, KLH35, ACSL3, SYRC, C16L2, NBEA, TBB3, XPO4, RBCC1, LRP1B, CAC1F, PRG4, BIR1B, SRCN1, SHRM3, ING1, MACF1, ACL7A, SMK2B, H17B6, RPGR, RHG07, MAST1, ADA11, TIM, PFKAP, IRAG1, DEMA, P2R3D, SETBP, NEK4, PLD1
Species: Mus musculus
Download
Burt RA, Dejanovic B, Peckham HJ, Lee KA, Li X, Ounadjela JR, Rao A, Malaker SA, Carr SA, Myers SA. Novel Antibodies for the Simple and Efficient Enrichment of Native O-GlcNAc Modified Peptides. Molecular & cellular proteomics : MCP 2021 20 34678516
Abstract:
Antibodies against posttranslational modifications (PTMs) such as lysine acetylation, ubiquitin remnants, or phosphotyrosine have resulted in significant advances in our understanding of the fundamental roles of these PTMs in biology. However, the roles of a number of PTMs remain largely unexplored due to the lack of robust enrichment reagents. The addition of N-acetylglucosamine to serine and threonine residues (O-GlcNAc) by the O-GlcNAc transferase (OGT) is a PTM implicated in numerous biological processes and disease states but with limited techniques for its study. Here, we evaluate a new mixture of anti-O-GlcNAc monoclonal antibodies for the immunoprecipitation of native O-GlcNAcylated peptides from cells and tissues. The anti-O-GlcNAc antibodies display good sensitivity and high specificity toward O-GlcNAc-modified peptides and do not recognize O-GalNAc or GlcNAc in extended glycans. Applying this antibody-based enrichment strategy to synaptosomes from mouse brain tissue samples, we identified over 1300 unique O-GlcNAc-modified peptides and over 1000 sites using just a fraction of sample preparation and instrument time required in other landmark investigations of O-GlcNAcylation. Our rapid and robust method greatly simplifies the analysis of O-GlcNAc signaling and will help to elucidate the role of this challenging PTM in health and disease.